Mineralys (MLYS) CCO Eric Warren Sells Shares After Option Exercise

What Happened
Eric Warren, Chief Commercial Officer of Mineralys Therapeutics (MLYS), exercised 7,438 stock options and immediately sold those 7,438 shares on Sept. 21, 2026. He paid $13.24 per share to exercise (total cost $98,479) and sold the shares in the open market at a weighted-average price of $28.12 for proceeds of $209,136 — implying a gross gain of roughly $110,657 before fees and taxes. The transaction was reported on Sept. 22, 2026 (timely filing).

Key Details

• Transaction date: 2026-09-21 (reported 2026-09-22).
• Option exercise: 7,438 shares acquired at $13.24 each (total $98,479). (Code M)
• Open-market sale: 7,438 shares sold at weighted-average $28.12 (range $27.94–$28.21) for $209,136. (Code S)
• A second derivative line showing disposition at $0 reflects the conversion/settlement of the exercised option into common shares.
• These sales were executed under a Rule 10b5-1 trading plan adopted March 27, 2026 (footnote F1).
• Vesting note: the underlying option vests 25% after one year, then monthly over 36 months (footnote F3).
• Shares owned after the transaction are not specified in the information provided.

Context

• This was an exercise followed by an immediate sale (a common cashless-type transaction) and was done under a pre-established 10b5-1 plan, which typically schedules sales independent of immediate market views.
• Sales under 10b5-1 plans are often routine and do not necessarily signal the insider’s current opinion of the company.